Mark J. Foley - Feb 2, 2022 Form 4 Insider Report for Revance Therapeutics, Inc. (RVNC)

Role
CEO, Director
Signature
/s/ Terri McDowell, Attorney-in-Fact
Stock symbol
RVNC
Transactions as of
Feb 2, 2022
Transactions value $
$0
Form type
4
Date filed
2/4/2022, 07:35 PM
Previous filing
Jan 5, 2022
Next filing
Mar 17, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RVNC Employee Stock Option (Right to Buy) Award $0 +143K $0.00 143K Feb 2, 2022 Common Stock 143K $13.08 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the stock option shall vest in forty-eight (48) equal monthly installments beginning from February 2, 2022, subject to Mr. Foley's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date.